• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Tryngolza Backing Could Be A Big Moment For Swedish Orphan Biovitrum Stock

    Simply Wall St·10/15/2026 10:32:54
    Listen to the news
    • Sobi UK reported that NICE issued final draft guidance in 2026 recommending Tryngolza (olezarsen) for adults with genetically confirmed familial chylomicronaemia syndrome in England and Wales when diet and standard triglyceride lowering drugs have not given adequate control.
    • The guidance is based on Phase 3 BALANCE results, where Tryngolza 80 mg cut fasting triglycerides versus placebo and reduced acute pancreatitis events, which ties directly into Swedish Orphan Biovitrum’s rare disease focus and potential future demand for high value metabolic therapies.
    • We will now look at how Swedish Orphan Biovitrum's investment narrative might shift as NICE backs Tryngolza for ultra rare FCS patients.

    Scan the rare disease space for more potential Swedish Orphan Biovitrum peers by checking out 614 high quality undiscovered gems, which focuses on high value treatments for overlooked conditions.

    Swedish Orphan Biovitrum Investment Narrative Recap

    To own Swedish Orphan Biovitrum, you need to buy into a rare disease specialist that is leaning heavily on higher value therapies and broader geographic reach. The thesis rests on execution. Multiple launches, label expansions and new affiliates all need to turn into sustained demand strong enough to support management’s long term margin ambitions.

    The NICE backing for Tryngolza in ultra rare FCS slots into that story as a proof point, but by itself is a small piece of the near term picture. The bigger swing factor remains how quickly the wider portfolio, including Altuvoct and Aspaveli, scales against rising launch spend and the current pressure on net profit margins.

    Among recent developments, the Phase 3 CORE and CORE2 data for Tryngolza in severe hypertriglyceridaemia look most connected to the NICE news. Those results, together with the BALANCE study in FCS, frame Tryngolza as a potential pillar asset within Swedish Orphan Biovitrum’s metabolic disease push, if reimbursement and uptake in multiple regions follow.

    For catalysts, that same program also illustrates the main operational risk. The business is committing to higher costs to support late stage assets and a larger commercial footprint, while profitability guidance for 2026 is already lower than the 2025 margin. If Tryngolza and its peers in gout and hemophilia ramp more slowly than expected, earnings could stay under pressure while the expanded cost base is already locked in.

    Swedish Orphan Biovitrum's current analyst narrative points to SEK 42.1b in revenue and SEK 9.2b in earnings by 2029, based on a forecast revenue growth rate of 11.2% per year and a move from SEK 1.4b in earnings today to that 2029 consensus. This implies an increase of SEK 7.8b over the period.

    Uncover how Swedish Orphan Biovitrum's fair value indicates a 15% potential upside to its current price before that discount feels fully reflected in Swedish Orphan Biovitrum.

    OM:SOBI 1-Year Stock Price Chart
    OM:SOBI 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame Tryngolza as a future growth engine for Swedish Orphan Biovitrum, even before this NICE decision, and were already pencilling in SEK 46.9b of revenue and SEK 12.3b of earnings by 2029. You can see how far opinions differ and why this news might reshape those projections.

    Explore 2 other Swedish Orphan Biovitrum fair value estimates, including one that suggests as much as 162% upside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Swedish Orphan Biovitrum?

    Once you have formed a view on Swedish Orphan Biovitrum, it can help to compare that thesis with other opportunities that share similar qualities or offer a different risk and income profile.

    • If capital preservation and smoother returns matter most to you, consider screening for companies with steadier risk profiles via 222 resilient stocks with low risk scores that may better align with a more cautious approach.
    • For investors focused on cash returns, use 216 dividend fortresses to spot income plays that pair higher yields with businesses that aim to keep payouts flowing.
    • When balance sheet strength is a priority, filter for financially resilient businesses through the list of solid balance sheet and fundamentals (202 results) to compare more durable profiles against your Swedish Orphan Biovitrum view.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.